Back
82· Surging
Health & Science2h 18m ago
The U.S. Food and Drug Administration has officially approved Kisunla (donanemab), a drug designed to slow the progression of cognitive decline in adults with early-stage Alzheimer's disease.
Silver Spring, MD, USA
Who
Eli Lilly & Co. / U.S. FDA
What
The U.S. Food and Drug Administration has officially approved Kisunla (donanemab), a drug designed to slow the progression of cognitive decline in adults with early-stage Alzheimer's disease.
When
Wed, 10 Jun 2026 07:50:07 GMT · 2h 18m ago
Where
Silver Spring, MD, USA · 39.0227°N, 77.0189°W
Why
Clinical trials demonstrated a 35% slowing of cognitive decline by clearing amyloid plaques from the brain, providing a third major pharmaceutical option for Alzheimer's patients.
The Frontline Impact
How this affects you
Patients now have another therapeutic option alongside Leqembi, though high costs and the need for frequent brain scans for safety monitoring remain hurdles to widespread accessibility.
Story chain
1 event in this threadNo related history yet — this is the origin event.
Verified Sources & Citations
Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.